Cellular immunotherapy for leukemia

[1]  H. Shiku,et al.  Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. , 2011, Blood.

[2]  N. Kadowaki,et al.  A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co‐pulsed with WT1 peptide and zoledronate , 2011, British journal of haematology.

[3]  N. Kadowaki,et al.  Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. , 2011, Experimental hematology.

[4]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[5]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[6]  H. Goossens,et al.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.

[7]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  J. Kutok,et al.  Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation , 2009, Proceedings of the National Academy of Sciences.

[9]  W. Stock,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). , 2009, Blood.

[10]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[11]  E. Thiel,et al.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.

[12]  J. Karp,et al.  Novel postremission strategies in adults with acute myeloid leukemia , 2009, Current opinion in hematology.

[13]  R. Schlenk,et al.  RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. , 2008, Blood.

[14]  K. Rezvani,et al.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. , 2007, Blood.

[15]  H. Erba.  Prognostic factors in elderly patients with AML and the implications for treatment. , 2007, Hematology. American Society of Hematology. Education Program.

[16]  K. Samuel,et al.  Phase I/II study of vaccination with dendritic‐like leukaemia cells for the immunotherapy of acute myeloid leukaemia , 2006, British journal of haematology.

[17]  J. Roliński,et al.  Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. , 2006, International journal of oncology.

[18]  H. Döhner,et al.  Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. , 2005, Blood.

[19]  A. Palucka,et al.  Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.

[20]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Je-Jung Lee,et al.  Immunotherapy using autologous monocyte‐derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation , 2004, Journal of clinical apheresis.

[22]  E. Thiel,et al.  Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity , 2004, Leukemia.

[23]  I. Kawase,et al.  Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis , 2003, International journal of hematology.

[24]  S. Fujii,et al.  Treatment of Post-Transplanted, Relapsed Patients with Hematological Malignancies by Infusion of HLA-Matched, Allogeneic-Dendritic Cells (DCs) Pulsed with Irradiated Tumor Cells and Primed T Cells , 2001, Leukemia & lymphoma.

[25]  S. Fujita,et al.  HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. , 2000, Blood.

[26]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[27]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.